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Abstract
HIV-1 co-infection is a leading cause of susceptibility to tuberculosis (TB), with the risk of TB
being increased at all stages of HIV-1 infection. Antiretroviral treatment (ART) is the most
effective way to reduce the risk of TB in HIV-1 co-infected people. Studying protective, ART-
induced, immune restoration in HIV-1 infected individuals sensitised by Mycobacterium
tuberculosis (Mtb) can thus help identify mechanisms of protection against TB. In order to
understand ART-mediated prevention of TB in HIV-1 infected adults, we investigated the
expression of 30 genes in whole blood from HIV-1 infected patients during the first 6 months
of ART-induced immune reconstitution. The 30 selected genes were previously described to
be differentially expressed between sorted Mtb specific central and effector memory CD4 T
cells. HIV-1 infected persons sensitised by Mtb were recruited in Khayelitsha, South Africa,
when initiating ART. RNA was extracted from whole blood at initiation and 1, 3 and 6 months
of ART. qRT-PCR was used to determine gene expression and three reference ‘housekeep-
ing’ genes were used to calculate the fold change in the expression of each gene relative to
day 0 of ART. Results were assessed longitudinally. We observed a decrease in the expres-
sion of a number of genes at 6 months of ART, reflecting a decrease in immune activation.
However, following correction for multiple comparisons and increasing CD4 counts, only the
decrease in CD27 gene expression remained statistically significant. While not statistically
significant, a number of genes also showed increased expression at various timepoints,
illustrating the broad regeneration of the T cell pool in HIV-1 infected adults on ART. Our
findings generate hypotheses underlying ART- induced protective immune reconstitution
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Introduction
Tuberculosis (TB) is the leading bacterial cause of death worldwide [1] and HIV infected per-
sons are 20–30 times more likely to develop TB than HIV uninfected persons, who have a
5–10% chance of developing active TB in their lifetime [2]. HIV-1 co-infection is the leading
cause of susceptibility to TB, and antiretroviral treatment (ART) is the most effective way to
reduce the risk of TB in HIV-1 co-infected persons, reducing tuberculosis incidence by up to
67% [3]. In order to identify mechanisms of ART-mediated prevention of TB in HIV-1
infected persons, we longitudinally analysed a group of HIV-1 infected persons starting ART.
Our hypothesis was that this highly susceptible group, who undergo immune restoration
through ART and thereby become less susceptible to TB, will yield insight into understanding
protective mechanisms against human TB. A previous longitudinal follow-up of 19 HIV
infected adults with Mycobacterium tuberculosis (Mtb) sensitisation over 48 weeks of ART
showed that the strongest correlate of increased ART mediated immunity was the expansion
of the less differentiated central memory CD4 T cell pool [4].
The importance of central memory T cells (TCM) in protection against TB has been
highlighted by studies addressing the mechanisms of action of promising vaccine candidates,
using animal models. The subunit vaccine H1 (containing Ag85B and ESAT-6) boosts
CD4+KLRG1-IL-2-secreting TCM [5]; the recombinant BCG DeltaureC::hly vaccine mediated
protection is based on the expansion of central memory CD4 T cells that are CXCR5+CCR7+
and express low levels of the transcription factors T-bet and Bcl-6 [6] the sustained protection
induced by the H56/CAF01 subunit vaccine was mediated by the less differentiated lung
parenchyma homing CD4 T cells that express low levels of KLRG1 and secrete high amounts
of IL-2 and IL-17A [7]. In humans, Mtb infected adolescents were followed longitudinally in
order to understand the mechanisms underlying progression from infection to pulmonary TB
disease. Those who progressed from latent infection to active TB disease displayed T cell acti-
vation (indicated by elevated expression of HLA-DR on CD4 T cells) and a decrease in relative
proportions of CD45RA-CCR7+ central memory CD4 and CD8 T cells [8]. More recently,
Chiacchio et al found that antiretroviral and anti-tuberculosis therapies significantly increased
the frequency of Mtb specific CD4 T cells in HIV-TB co-infected patients with an increase in
the central memory compartment [9]. Overall, these findings support the role of central mem-
ory CD4 T cells as potential correlates of protection in TB.
To broadly investigate the ART-induced reconstitution of the T cell pool in HIV-1 infected
persons during the first 6 months of ART, we performed quantitative RT-PCR using RNA
extracted from whole blood, for genes selected on the basis of differential expression between
sorted Mtb specific TCM and effector memory (TEM) CD4 T cells as described [10]. Thus
ICOS, SELL, PRKCA, TCF7L, LEF1, NFKB1, CD38, ITK, IGF1R, ARHGEF18, AXIN2, CCR7
and CD27 had a significantly higher expression in sorted Mtb specific TCM compared to TEM
while the genes GNLY, RORC, TGFB1, PRF1, CCL5, IFNG, CCR2, GATA, GZMA, GZMB,
GZMK, PRR5L, TXB21, IL2RB, CCR4, CCR5 and FAM129A had a significantly higher expres-
sion in sorted Mtb specific TEM compared to TCM. We evaluated the change in gene expres-
sion during the first 6 months of ART and hypothesised that the transcription of central
memory T cell associated genes would increase over time in HIV infected persons during the
first 6 months of ART.
T cell gene expression in whole blood during antiretroviral treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0209516 December 27, 2018 2 / 13
(FC001218), Cancer Research UK (FC001218) and
Wellcome (FC001218). The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Materials and methods
Study population and sample collection
Ethical approval for the study was obtained from the University of Cape Town Faculty of
Health Sciences Human Research Ethics Committee (HREC 245/2009 and 545/2010). All par-
ticipants gave written informed consent in accordance with the Declaration of Helsinki. HIV
infected persons starting ART were recruited from the Ubuntu Clinic in Khayelitsha, South
Africa, during two longitudinal studies in 2011–2012. The two cohorts have previously been
described [11, 12]. Measurement of CD4 count and HIV viral load was performed by the
South African National Health Laboratory Service by flow cytometry and polymerase chain
reaction respectively. Blood for RNA extraction was collected in Tempus tubes at baseline and
after one (1M), three (3M) and six months (6M) of receiving ART, and stored for future use.
Additional blood was collected to establish Mtb sensitisation using the Quantiferon Gold In-
tube (QFT) assay and an in-house Enzyme-Linked ImmunoSpot assay (ELISpot) as described
[12].
RNA Isolation and characterisation
Tubes were stored at -20˚C until batched processing using the Tempus Spin RNA Isolation kit
(Thermofisher) according to the manufacturer’s recommendations. RNA quantity and quality
(integrity) were assessed by a Nanodrop 2000c spectrophotometer (Thermo Scientific) and an Agi-
lent RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer. RNA was reverse transcribed to cDNA
using the SuperScript III First-Strand Synthesis System for RT-PCR, using 9μL RNA in a total
reaction volume of 20μL per sample in a Bio-Rad thermocycler at 50˚C for 50 minutes followed by
termination at 85˚C for 5 minutes and a hold at 4˚C. cDNA was stored at -20˚C until use.
RT-PCR using TaqMan Fast Advance Mastermix and probes
Thirty memory T cell specific genes were selected for analysis based on significantly elevated
expression in sorted Mtb-specific TCM (13 genes) and TEM (17 genes). The selection of genes
was based on results from a previous study [10], comparing the expression of 96 genes mea-
sured by microfluidic RT-PCR in Mtb-specific CD4+ T cells identified by HLA class II tetra-
mers, sorted based on the surface expression of CD45RA, CCR7 and CD27, and classified into
naïve, stem cell like memory, central memory and effector memory phenotype. We selected
the genes that were differentially expressed between the sorted Mtb specific central memory
and effector memory T cells (S1 Table). Based on a recent systematic review of endogenous
controls in gene expression studies [13], we included three reference genes, 18S, ACTB and
GAPDH, in order to increase the stringency of the analysis. TaqMan probes used for RT-PCR
are summarised in S1 Table. Eighteen μL mastermix containing 10μL TaqMan Fast Advance
Master Mix (2x), 1 μL TaqMan PDAR and 7μL nuclease-free water, was added to all wells in a
96-well optical reaction plate, with each well containing 2μL of sample cDNA. The plate was
run on a QuantStudio 7 Flex (Applied Biosystems) in fast mode, for 40 cycles, as follows: poly-
merase activation at 95˚C for 20 seconds, denaturation at 95˚C for 1 second, extension at 60˚C
for 20 seconds. Quantstudio 6 and 7 Flex Real-Time PCR software (Applied Biosystems) was
used for the instrument setup. This software measures the PCR cycle at which the gene of
interest begins to exponentially expand above the threshold limit, referred to as the Ct value.
Data analysis
Ct values were normalised to the reference genes 18S, ACTB and GAPDH. Inspection of the
raw Ct values for the three reference genes indicated no significant change in the median and
T cell gene expression in whole blood during antiretroviral treatment
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IQR at all timepoints (Fig 1). Based on this, we normalised our gene of interest Ct values to the
average expression of the three reference genes at each timepoint. Thus, Delta Ct was calcu-
lated using the formula: Delta Ct = Ct (gene of interest) at timepoint—Ct (average of reference
genes) at timepoint, timepoint meaning day 0, 1M, 3M, 6M respectively. Transcripts that failed
to amplify during the 40 cycles from all samples, were excluded from analysis. Next, we calcu-
lated the fold change in the expression of each gene relative to day 0 of ART, using the formula:
Fold Change = 2^ [(Delta Ct at timepoint)—(Delta Ct at D0)]. In order to account for the fact
that we used bulk RNA extracted from whole blood to evaluate T cell specific genes, and that
the CD4 T cell counts increased over time due to ART (Table 1), we further calculated the
CD4 count corrected fold change using the formula: Corrected Fold change (at timepoint) =
Fold Change / [(CD4 at timepoint / CD4 at D0)]. Increased gene expression is indicated by
fold change values of> 1.
Fig 1. Ct values of the reference genes 18S, ACTB and GAPDH indicated no significant change in the median and
IQR at all timepoints.
https://doi.org/10.1371/journal.pone.0209516.g001
Table 1. Effect of ART on CD4 counts and Viral loads of patients longitudinally, and sensitisation to Mtb as determined by interferon gamma release assays.
Median (IQR) HIV Infected Persons on ART (n = 48)
Time on ART Day 0 1M 3M 6M
CD4 count (cells/μl blood) 199
(115–255)
275
(182–366)
301
(191–372)
320
(218–426)
Viral Load� (copies/mL blood) 79253
(40345–209 238)
316
(123–643)
40
(39–108)
40
(39–40)
QFT Gold InTube
(IU/ml)
1.5 (0.51–7.3)
(n = 48)
1.7 (0.21–12)
(n = 41)
0.73 (0.18–6.9)
(n = 38)
1.6 (0.17–4.8)
(n = 34)
% positive by QFT Gold InTube 65 63 46 42
ELISpot
(SFC/million PBMC)
28 (4–230)
(n = 41)
72 (14–540)
(n = 41)
70 (20–496)
(n = 38)
72 (21–198)
(n = 34)
% positive by ELISpot�� 56 63 66 54
� Limit of detection is 40 and the value assigned to <40 copies/ml was 39.
�� Defined as� 29 SFC/million PBMC.
https://doi.org/10.1371/journal.pone.0209516.t001
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Flow cytometry analysis
Cryopreserved peripheral blood mononuclear cells were thawed, counted, rested and stained
for the following surface markers: CD14 (APC-cy7), CD3 (BV785), CD4 (PE-cy7), CD8 (V500),
CD45RA (BV570), CD27 (BV711), CD62L (FITC), CD38 (APC) and viability dye (APC-Cy7).
Following washing, cells were acquired on a LSR-II (BD) and analysed using FlowJo.
Statistical analysis
Data was analysed using GraphPad Prism (version 6.0) for Mac. The Normality of the data was
determined using the D’Agostino and Pearson normality test. Unpaired data that was not nor-
mally distributed was analysed using the Mann-Whitney U test. Correction for multiple com-
parisons was performed using Bonferroni correction by multiplying p values with the number
of comparisons (n)-1.
Results
Blood stored in Tempus tubes for RNA extraction was available from n = 48 HIV infected per-
sons (36 females, 12 males, median age 35 years, IQR 29–38) at all follow up timepoints, all of
whom were sensitised by Mtb as determined by interferon gamma release assays QFT and ELI-
Spot (Table 1 and Fig 2). While not all patients had samples available for testing Mtb sensitisa-
tion at all timepoints, all patients were positive by at least one assay on at least one timepoint
during the longitudinal follow up, indicating Mtb sensitisation and we infer current or prior
latent TB infection. The effect of ART on CD4 counts and HIV viral loads of the patients is
also summarized in Table 1, showing that all patients experienced CD4 reconstitution and
viral load suppression during the longitudinal follow up. Thus, the median CD4 count
increased from 199 (IQR 115–255) to 320 (IQR 218–426) cells/μl blood and median HIV viral
load decreased from 79253 (IQR 40345–209238) to 40 (IQR 39–40) copies/mL blood between
day 0 and 6M of ART. There was no correlation between the ELISpot response and CD4 count
at any of the timepoints (Fig 3).
All transcripts were normalised to the average of the three references (18S, ACTB and
GAPDH) in order to generate Delta-Ct values. The fold change in the expression of each gene
Fig 2. MTB sensitisation of the patients as determined by interferon gamma release assays QFT-gold in-tube (cutoff 0.35 IU/ml) and in house ELISpot (cut-off 20
spot forming cells per million PBMC). All patients were positive in at least one assay, at least one timepoint during the longitudinal follow up.
https://doi.org/10.1371/journal.pone.0209516.g002
T cell gene expression in whole blood during antiretroviral treatment
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relative to day 0 of ART, was calculated and summarized in Table 2. Several genes showed an
increase at various time points, including CCL5, IL2RB and TBX21 showing an increased
expression relative to day 0 at both 1M and 3M of ART. However, those showing an increase
at all three time points (1M, 3M and 6M) were CD38 and SELL (Table 2, fold change values
highlighted in bold). A number of genes showed a significantly decreased expression at 6M of
ART, such as CD27, LEF1, CCL5, CCR4, CCR5, FAM129A, GZMK and IL2RB (Table 2, p val-
ues in bold). Bonferroni correction for multiple comparisons resulted in none of these changes
remaining statistically significant.
Since the selected genes were previously found to be preferentially expressed on sorted CD4
T cells while we isolated RNA from whole blood, as opposed to sorted memory CD4 T cells,
we further explored correction of the results for the fold change in CD4 counts per mL of
blood related to day 0 of ART, to account for the fact that the number of CD4 T cells per mL
blood was increasing as a result of successful ART (results summarised in Table 3). It was
interesting to find that only the CD38 gene showed an increased expression relative to day 0 at
1M and 3M of ART, while the PRF1 gene showed a slight increase relative to day 0 at 1M of
ART. At the same time, ARGHEF18, CD27, LEF1, CCL5, FAM129A, GZMK and RORC
showed a significantly decreased expression (Table 3, p values in bold). Following Bonferroni
correction for multiple comparisons however, only the decrease in CD27 gene expression
remained statistically significant.
Fig 3. Elispot responses expressed as spot forming cells per million PBMC, related to CD4 counts in cells per microliter blood, at each
timepoint. There was no correlation between the ELISpot response and the CD4 counts.
https://doi.org/10.1371/journal.pone.0209516.g003
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The overlap of genes that showed significant decrease over time both with and without cor-
rection for increasing CD4 counts were CD27, LEF1, CCL5, FAM129A and GZMK, as illustrated
in Fig 4. In a subset of patients with available stored PBMC, we performed flow cytometry
experiments to assess the surface expression of CD27, CD62L (encoded by SELL) and CD38 on
CD3+ and CD3+CD4+ lymphocytes. While this experiment was limited by the number of
patients with remaining frozen PBMC and hence the numbers are too small to perform mean-
ingful statistical analyses, the results support a trend in decreasing CD27 at protein level (Fig 5).
Discussion
In order to identify mechanisms of ART-mediated prevention of TB in HIV-1 infected per-
sons, we investigated the expression of 30 selected genes longitudinally in Mtb sensitised
Table 2. Fold change (median and IQR) of gene expression between day 0 and 1M, 3M, 6M of ART, without correction for CD4 counts. Increased gene expression is
indicated by values>1. p-values listed compare gene expression between day 0 and 6 months of ART, as well as after Bonferroni correction for multiple comparisons
(pcorr
�).
Gene 1M 3M 6M p value pcorr
�
TCM specific genes
ARGHEF18 1.1 (0.59–2) 0.97 (0.39–2.9) 0.86 (0.019–1.9) 0.164 ns
AXIN2 0.7 (0.15–1.5) 0.74 (0.054–1.6) 0.51 (0.078–1) 0.464 ns
CCR7 0.82 (0.39–1.4) 0.83 (0.41–1.5) 0.49 (0.0051–1.1) 0.094 ns
CD27 1 (0.69–1.7) 0.93 (0.35–1.8) 0.58 (0.0032–1.1) 0.010 ns
CD38 1.6 (0.61–3.3) 1.7 (0.12–3.1) 1.1 (0.014–3.7) 0.387 ns
ICOS 0.97 (0.37–1.6) 1.2 (0.32–2.3) 0.69 (0.054–2.3) 0.515 ns
IGF1R 0.6 (0.42–0.99) 0.62 (0.22–2.2) 0.54 (0.0059–1.4) 0.391 ns
ITK 1 (0.25–2.7) 1.1 (0.15–4.2) 0.65 (0.013–2.4) 0.308 ns
LEF1 0.94 (0.36–2.2) 0.91 (0.11–3.6) 0.4 (0.018–1.1) 0.028 ns
NFKB1 0.85 (0.44–1.8) 1 (0.48–2.5) 0.88 (0.0046–1.7) 0.384 ns
PRKCA 0.52 (0.069–5.2) 0.23 (0.01–1.6) 0.47 (0.0096–5.4) 0.617 ns
SELL 1.3 (0.67–1.8) 1.2 (0.5–2.1) 1.3 (0.21–1.8) 0.438 ns
TCF7L2 1.6 (0.57–2.4) 0.79 (0.17–3) 0.69 (0.012–3.7) 0.217 ns
TEM specific genes
CCL5 1.1 (0.6–1.5) 1.3 (0.54–2.1) 0.63 (0.23–1.6) 0.031 ns
CCR2 0.62 (0.36–1.2) 0.77 (0.075–1.9) 0.29 (0.019–1.3) 0.120 ns
CCR4 0.85 (0.42–1.5) 0.46 (0.057–1.4) 0.38 (0.01–1.2) 0.033 ns
CCR5 1.1 (0.67–1.8) 0.77 (0.14–2) 0.3 (0.026–2.8) 0.049 ns
FAM129A 1.1 (0.53–1.8) 0.91 (0.47–1.7) 0.7 (0.012–1.1) 0.015 ns
GATA3 0.77 (0.36–1.8) 0.5 (0.2–1.2) 0.47 (0.0025–1.6) 0.247 ns
GNLY 0.69 (0.39–1.3) 0.99 (0.46–1.9) 0.63 (0.21–1.3) 0.434 ns
GZMA 1.1 (0.55–1.7) 0.94 (0.5–2.8) 0.72 (0.074–2) 0.184 ns
GZMB 0.94 (0.46–1.8) 1.3 (0.29–3.1) 0.61 (0.023–1.7) 0.109 ns
GZMK 0.91 (0.49–1.4) 0.85 (0.34–2.2) 0.54 (0.022–1.2) 0.047 ns
IFNG 0.86 (0.34–1.9) 1.4 (0.29–2.8) 0.4 (0.0037–2.4) 0.292 ns
IL2RB 1.1 (0.39–1.7) 1.7 (0.3–3.2) 0.54 (0.0031–1.5) 0.038 ns
PRF1 1.5 (0.28–11) 0.82 (0.14–8.6) 0.5 (0.019–3.1) 0.052 ns
PRR5L 1.3 (0.47–2.8) 0.86 (0.2–1.9) 0.67 (0.011–2.2) 0.099 ns
RORC 0.75 (0.34–2.1) 0.25 (0.0001–2.4) 0.026 (0.0008–0.62) 0.077 ns
TBX21 1.2 (0.31–4.6) 1.1 (0.096–4.8) 0.67 (0.0068–4.8) 0.292 ns
TGBF1 1.1 (0.54–1.4) 0.85 (0.33–2.1) 1.1 (0.11–1.7) > 0.999 ns
‘ns’ indicates ‘not significant’
https://doi.org/10.1371/journal.pone.0209516.t002
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persons starting ART, using qRT-PCR. The genes included cytokines and cytokine receptors,
chemokine receptors, inhibitory molecules, co-stimulatory molecules, kinases, transcription
factors, molecules that play a role in homing and migration and effector molecules. Overall, 13
genes: ICOS, SELL, PRKCA, TCF7L, LEF1, NFKB1, CD38, ITK, IGF1R, ARHGEF18, AXIN2,
CCR7 and CD27, had previously been shown to have a higher expression in sorted Mtb specific
TCM while 17 genes: GNLY, RORC, TGFB, PRF1, CCL5, IFNG, CCR2, GATA3, GZMA,
GZMB, GZMK, PRR5L, TXB21, IL2RB, CCR4, CCR5 and FAM129A had been shown to have a
higher expression in sorted Mtb specific TEM [10].
The results indicated significantly decreased gene expression for a number of genes at 6
months of ART, reflecting a decrease in immune activation as a result of decreasing HIV viral
load. However, following correction for multiple comparisons, only the decrease in CD27
Table 3. Fold change (median and IQR) of gene expression between day 0 and 1M, 3M, 6M of ART, with correction for increasing CD4 counts. Increased gene
expression is indicated by values>1. p-values listed compare gene expression between day 0 and 6 months of ART, as well as after Bonferroni correction for multiple com-
parisons (pcorr
�).
Gene 1M 3M 6M p value pcorr
�
TCM specific genes
ARGHEF18 0.88 (0.43–1.2) 0.68 (0.3–1.8) 0.52 (0.21–1) 0.047 ns
AXIN2 0.71 (0.13–1.3) 0.5 (0.15–1) 0.21 (0.085–0.57) 0.121 ns
CCR7 0.54 (0.23–1.1) 0.54 (0.21–0.94) 0.28 (0.15–0.72) 0.071 ns
CD27 0.77 (0.49–1.6) 0.85 (0.31–1.3) 0.4 (0.16–0.55) 0.001 0.03
CD38 1.3 (0.62–2) 1.1 (0.48–2.6) 0.81 (0.32–2.5) 0.383 ns
ICOS 0.58 (0.32–1.3) 0.81 (0.4–1.3) 0.46 (0.21–1.5) 0.601 ns
IGF1R 0.45 (0.31–0.96) 0.39 (0.16–1.7) 0.33 (0.11–0.8) 0.213 ns
ITK 0.82 (0.18–2.5) 0.73 (0.29–2.5) 0.53 (0.15–1.6) 0.688 ns
LEF1 0.49 (0.27–2) 0.65 (0.15–3.9) 0.3 (0.05–0.67) 0.040 ns
NFKB1 0.7 (0.28–1.3) 0.77 (0.27–1.4) 0.51 (0.22–0.9) 0.254 ns
PRKCA 0.48 (0.12–2.8) 0.2 (0.015–1.8) 0.32 (0.055–3.7) 0.579 ns
SELL 0.93 (0.54–1.4) 0.74 (0.49–1.3) 0.83 (0.3–1.3) 0.462 ns
TCF7L2 1 (0.36–2.3) 0.77 (0.19–2.9) 0.66 (0.08–2.1) 0.216 ns
TEM specific genes
CCL5 0.77 (0.51–1.2) 0.84 (0.42–1.3) 0.45 (0.16–0.81) 0.007 ns
CCR2 0.47 (0.2–0.84) 0.44 (0.058–1.7) 0.29 (0.073–0.92) 0.351 ns
CCR4 0.6 (0.34–1.4) 0.34 (0.075–1.1) 0.33 (0.033–1) 0.056 ns
CCR5 0.85 (0.46–1.4) 0.58 (0.14–1.4) 0.29 (0.055–1.6) 0.054 ns
FAM129A 0.74 (0.48–1.3) 0.51 (0.34–1.1) 0.48 (0.16–0.65) 0.004 ns
GATA3 0.52 (0.32–1.2) 0.39 (0.17–0.85) 0.43 (0.06–1.1) 0.350 ns
GNLY 0.54 (0.28–0.88) 0.64 (0.36–1.3) 0.35 (0.15–0.82) 0.328 ns
GZMA 0.67 (0.39–1.2) 0.66 (0.4–1.2) 0.47 (0.16–1.1) 0.148 ns
GZMB 0.76 (0.31–1.2) 0.81 (0.37–2.3) 0.39 (0.11–0.73) 0.064 ns
GZMK 0.59 (0.34–1.6) 0.61 (0.25–1.5) 0.33 (0.11–0.67) 0.016 ns
IFNG 0.6 (0.25–1.4) 0.99 (0.32–1.5) 0.77 (0.05–1.3) 0.446 ns
IL2RB 0.68 (0.29–1.1) 0.95 (0.38–1.9) 0.31 (0.033–0.91) 0.066 ns
PRF1 1.1 (0.27–6.3) 0.67 (0.23–7.1) 0.51 (0.085–2) 0.120 ns
PRR5L 0.88 (0.37–1.6) 0.58 (0.18–1.6) 0.75 (0.13–2) 0.351 ns
RORC 0.83 (0.3–2.1) 0.39 (0–1.7) 0.09 (0–0.4) 0.008 ns
TBX21 0.75 (0.26–2.7) 0.69 (0.14–3.5) 0.59 (0.18–2) 0.470 ns
TGBF1 0.73 (0.38–1.1) 0.6 (0.3–1.3) 0.67 (0.29–1.2) 0.993 ns
‘ns’ indicates ‘not significant’
https://doi.org/10.1371/journal.pone.0209516.t003
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expression remained statistically significant. CD27 is present on the surface of CD4 T cells and
is a receptor involved in co-stimulation. CD27 downregulates as naïve T cells differentiate into
central memory T cells and subsequently effector memory T cells, thus central memory T cells
tend to express the CD27 while effector memory T cells lack the CD27 receptor [14]. CD27
expression on circulating Mtb-specific T cells has been shown to discriminate active tuberculo-
sis from latent tuberculosis infection in HIV uninfected adults and children, suggesting that
loss of CD27 expression could be due to persistent antigenic stimulation and might relate to
increased homing to the disease site [15, 16]. Studies involving HIV-infected persons showed
rapid depletion of Mtb–specific CD4 T cell responses early after HIV infection [17] and in con-
trast to HIV-uninfected, found that Mtb-specific CD4 T cell populations from HIV+LTBI
+ persons were often dominated by CD27-negative cells [18]. CD27 expression has been pro-
posed as a tool for active and latent TB diagnosis in HIV infected persons as well [16, 19], and
further studies indicated HLA-DR expression on Mtb-specific CD4 T cells to be promising
and comparable [20] ([21]. The impact of ART on the restoration of antigen-specific T cells
was shown to be dependent on the co-pathogen specific CD4 T cell memory phenotype, with
differences between Mtb-specific and CMV-specific memory CD4 cell reconstitution [9, 22].
However, the definition of the memory CD4 T cell is based on the expression of surface mark-
ers and a decrease in CD27 transcript detected in whole blood, as shown by our data, cannot
extrapolate to the restoration of memory CD4 T cells during ART, necessitating further studies
based on sorted memory cells.
Fig 4. Fold change of gene expression at 1M, 3M and 6M of ART, for the genes that showed significant change over time both with and without correction for
increasing CD4 count.
https://doi.org/10.1371/journal.pone.0209516.g004
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We also found increased gene expression at one month of ART for a number of genes, with
several showing an increase at three months as well. Only CD38 and SELL showed an increase
at all three timepoints studied. Human CD38 is the mammalian prototype of a family of pro-
teins which share structural similarities and an ectoenzymatic activity involved in the produc-
tion of calcium mobilizing compounds. CD38 is found on the surface of many immune cells
and plays a role in the regulation of intracellular calcium, that in turn controls numerous pro-
cesses such as cell activation and proliferation, hormone secretion and immune responses.
Besides the enzymatic activity, the molecule performs as a receptor, responsible for adhesion
and signalling in leukocytes [23]. SELL is the gene responsible for the transcription of L-selec-
tin, also known as, CD62L. The protein product of SELL is a homing receptor required by lym-
phocytes to enter secondary lymphoid tissues. CD62L is expressed on the surfaces of
lymphocytes and granulocytes, with central memory T cells expressing L-selectin to localize in
secondary lymphoid organs, and effector memory T cells not expressing CD62L [24].
We further explored the data with respect to the ART induced expansion of CD4 T cells, by
calculating the fold change corrected for the fold increase in CD4 counts. However, given the
broad cellular distribution of many of the molecules studied (such as CCR7, LEF, TCF1,
CD27, and CD62L being very abundant on CD8 T cells and other cells, while CD38 is even
more highly expressed on T cells other than CD4 T cells), normalization may not have been
necessary. Nevertheless, we thought it would be informative to see if changes to these genes
during ART can also be detected after normalization to CD4. It was interesting to see that the
number of genes showing an increased expression was more restricted, with only CD38 being
increased at 1M and 3M of ART, while PRF1 slightly increased at 1M of ART.
The activation of reference genes according to experimental and / or biological conditions
is an important factor to consider in gene expression studies, as reviewed [13, 25].
Fig 5. The proportion of (a) CD3+ and (b) CD3+CD4+ lymphocytes expressing CD27, CD62L and CD38 as determined by flow cytometry, using PBMC from a subset
of HIV infected patients on ART at various timepoints.
https://doi.org/10.1371/journal.pone.0209516.g005
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Additionally, 18S is more stable for T cell specific genes, while ACTB and GAPDH can be
more variable upon activation [25]. Considering that the genes we evaluated, while CD4 T cell
specific, could also be expressed by other T cell subsets, and that their expression could poten-
tially be affected by ART induced immune de-activation (in line with decreasing viral load on
ART), we elected to use the average expression of the three reference genes for the analysis.
Our study has several limitations that preclude any conclusion on the regulation of memory
CD4 T cells during ART: (1) the 30 genes included for analysis were identified in 7 HIV unin-
fected persons, while our results are based on samples from HIV infected persons during ART.
Thus, HIV infection in itself might potentially affect gene expression. (2) We did not have
RNA from an HIV uninfected control group. (3) We extracted RNA from whole blood as
opposed to sorted cell populations and (4) the genes evaluated are also expressed by non-CD4
T cells present in whole blood. Examination of isolated CD4 T cells alone could also have the
limitation of altered gene expression as a result of any manipulation involving the isolation of
specific T cell subsets, thus altering the gene expression reflected in bulk whole blood analyses.
We believe the answer is to perform single cell sequencing on sorted Mtb specific CD4 mem-
ory T cells and that is our intention in a future study. An additional limitation is that we did
not assess the effect of HIV on the gene expression of T cells in patients without ART, however,
as current guidelines recommend starting ART immediately after HIV diagnosis, this would
not be ethical. Moreover, HIV-1-specific T cells were previously assessed in patients with
advanced disease and showed, that while CD4+ T cell numbers increased substantially during
the first year of ART, the population did not normalize and the increases were largely due to
the expansion of tissue-derived CCR4+ central memory CD4 T cells [26]. A strength of our
study is using three different reference genes, and while the original set of 30 genes were deter-
mined in relation to beta-2-microglobulin (B2M), the potential generalisability of the findings
are illustrated by the fact that we used different reference genes.
In summary, we observed a decrease in the expression of a number of the selected genes at
various timepoints, illustrating an ART induced decrease in immune activation. In the same
time, a number of genes also showed increased expression at various timepoints, suggesting
the broad regeneration of the T cell pool in HIV-1 infected adults on ART. Our findings gener-
ate hypotheses underlying ART- induced protective immune reconstitution and may pave the
way for future studies to evaluate ART mediated prevention of TB in HIV-1 infected persons.
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